P3.18.37 A Phase 3 Trial of First-Line MK-3475A (Subcutaneous Pembrolizumab) for Stage IV NSCLC With PD-L1 TPS =50%

Articles > Article · 2025

Authors: T-E. Ciuleanu, R.A. Ramírez Fallas, Tuncay GÖKSEL, S.J. Kim, G. Song, S. Zhang, B. Halmos

Journal of Thoracic Oncology, International, WoS, 2025, vol 20, pp S560-S561